SPONSOR
Peking University Cancer Hospital & Institute
Total Trials
9
Recruiting
9
Phases
Phase 1, EARLY_Phase 1, Phase 2
Conditions studied: SCLC, Extensive StageTNBC - Triple-Negative Breast CancerBreast CancerMalignant Solid TumorsUrothelial CarcinomaNon-Small Cell Lung CancerB7H3CD276 AffibodyPET/CT ImaingOvarian Carcinoma
Peking University Cancer Hospital & Institute is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including SCLC, Extensive Stage, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Malignant Solid Tumors.
The trial portfolio spans Phase 1, EARLY_Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Peking University Cancer Hospital & Institute
How many clinical trials has Peking University Cancer Hospital & Institute sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Peking University Cancer Hospital & Institute, of which 9 are actively recruiting participants. These trials cover conditions including SCLC, Extensive Stage, TNBC - Triple-Negative Breast Cancer, Breast Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Peking University Cancer Hospital & Institute research focus on?
Peking University Cancer Hospital & Institute clinical trials span SCLC, Extensive Stage, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Malignant Solid Tumors, Urothelial Carcinoma, and additional conditions. The research pipeline includes Phase 1, EARLY_Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Peking University Cancer Hospital & Institute clinical trial?
To participate in a Peking University Cancer Hospital & Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Peking University Cancer Hospital & Institute trials with current recruitment status updated daily.
Clinical Trials by Peking University Cancer Hospital & Institute
NCT07413042 Phase 1
Recruiting
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
SCLC, Extensive Stage
NCT07046455
Recruiting
Trop-2 Targeted PET Probes in Advanced TNBC
TNBC - Triple-Negative Breast Cancer
NCT06909604
Recruiting
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Breast Cancer
NCT05579275 EARLY_Phase 1
Recruiting
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
Malignant Solid Tumors
NCT05321316
Recruiting
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Urothelial Carcinoma
NCT05104788 Phase 2
Recruiting
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT06454955 EARLY_Phase 1
Recruiting
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
B7H3
NCT06420973 Phase 2
Recruiting
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Ovarian Carcinoma
NCT06869239
Recruiting
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
Limited-stage Small Cell Lung Cancer (LS-SCLC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology